Autolus Therapeutics to Participate in Upcoming Investor Conferences
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in upcoming investor conferences.
William Blair 45th Annual Growth Stock Conference
Management to host investor meetings
Date: June 3, 2025
Location: Chicago, IL
Jefferies Global Healthcare Conference
Fireside Chat Presentation
Date and time: June 5, 2025; 3:10pm EDT / 20:10pm BST
Location: New York, NY
Presenter: Chief Executive Officer Dr. Christian Itin
Goldman Sachs 46th Annual Global Healthcare Conference
Fireside Chat Presentation
Date and time: June 11, 2025; 1:20pm EDT / 18:20 BST
Location: Miami, FL
Presenter: Chief Financial Officer Rob Dolski
A webcast of the fireside chats will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at . A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved and MHRA licensed product, obe-cel, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit .
Contact:
Amanda Cray
Olivia Manser
8
